Abstract
An intensive clinical research has been carried out over the past three decades aiming to avoid performing a total laryngectomy. Large partial open procedures or endoscopic laser CO2 surgery may be an alternative to total laryngectomy in very highly selected cases. Altered fractionated radiotherapy has proved to be more efficient than conventional radiotherapy. However, most of the research has been done by combining chemotherapy and radiotherapy. The first programs used induction chemotherapy (cisplatin and 5-fluorouracil with or without docetaxel) followed by radiotherapy in good responders. Toxicity was acceptable, neither disease control nor survivals were compromised and larynx could be preserved in at least two thirds of the cases. The second programs used concomitant chemoradiotherapy. Concurrent chemoradiotherapy provided higher larynx preservation rates but at the price of a substantial acute and late toxicity potentially compromising the larynx function. Alternating chemoradiotherapy did not increase toxicity but larynx preservation was similar to induction chemotherapy. Whether concurrent or alternating, there was no improvement of survival. The on-going third programs are assessing induction chemotherapy followed by radiotherapy with either concurrent chemotherapy or concurrent biotherapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chevalier D, Laccourreye O, Brasnu D, Laccourreye H, Piquet JJ. Cricohyoidoepiglottopexy for glottic carcinoma with fixation or impaired motion of the true vocal cord: 5-year oncologic results with 112 patients. Ann Otol Rhinol Laryngol. 1997;106:364–9.
Lima RA, Freitas EQ, Kligerman J, et al. Near-total laryngectomy for treatment of advanced laryngeal cancer. Am J Surg. 1997;174:490–1.
Iro H, Waldfahrer F, Altendorf-Hofmann A, Weidenbecher M, Sauer R, Steiner W. Transoral laser surgery of supraglottic cancer: follow-up of 141 patients. Arch Otolaryngol Head Neck Surg. 1998;124(11):1245–50.
Motta G, Esposito E, Motta S, Tartaro G, Testa D. CO(2) laser surgery in the treatment of glottic cancer. Head Neck. 2005;27:566–74.
Vilaseca-Gonzalez I, Bernal-Sprekelsen M, Blanch-Alejandro JL, Moragas-Lluis M. Complications in transoral CO2 laser surgery for carcinoma of the larynx and hypopharynx. Head Neck. 2003;25:382–8.
Martin A, Jäckel MC, Christiansen H, Mahmoodzada M, Kron M, Steiner W. Laryngoscope. 2008;118:398–402.
Rudert HH, Hoft S. Transoral carbon-dioxide laser resection of hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2003;260:198–206.
Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–54.
Decker DA, Drelichman A, Jacobs J, et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer. 1983;51:1353–5.
Ensley JF, Jacobs JR, Weaver A, et al. Correlation between response to cis-platinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 1984;54(5):811–4.
Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH–NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet. 2000;355:949–55.
The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685–90.
Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88:890–9.
Lefebvre J-L, Chevalier D, Luboinski B, et al. Is laryngeal preserÂvation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the EORTC 24891 trial. J Clin Oncol. 2004 ASCO Annual Meeting Proc. 2004;22:abstract 5531.
Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34:224–8.
Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–705.
Posner MR, Hershock DM, Biajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15.
Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101:498–506.
Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH–NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol. 2009;92:4–14.
Merlano M, Vitale V, Rosso R, et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 1992;327:1115–21.
Merlano M. Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative? Oncologist. 2006;11:146–51.
Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8.
Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol. 2006 ASCO Annual Meeting Proc.2006;24:abstract 5517.
Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: a RTOG analysis. J Clin Oncol. 2008;26:3582–9.
Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009;101:142–52.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and Neck. N Engl J Med. 2006;354:567–78.
Posner MR, Norris CM, Wirth LJ, et al. Sequential therapy for locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009;20:921–7.
Worden FP, Moyer J, Lee JS, et al. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope. 2009;119:1510–7.
Lefebvre JL, Pointreay Y, Rolland F, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study. PASCO Annual Meeting Proc. 2009:abstract 6010.
Lefebvre JL, Ang KK. Larynx preservation clinical trial design: key issues and recommendations – a consensus panel summary. Int J Radiat Oncol Biol Phys. 2009;73:1293–303.
Lefebvre JL, Ang KK. Larynx preservation clinical trial design: key issues and recommendations – a consensus panel summary. Head Neck. 2009;31:429–41.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Lefebvre, JL. (2011). Programs of Organ and Function Preservation. In: Bernier, J. (eds) Head and Neck Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9464-6_23
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9464-6_23
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-9463-9
Online ISBN: 978-1-4419-9464-6
eBook Packages: MedicineMedicine (R0)